Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg(Columbia University), Alberico L. Catapano(University of Milan), Carlos A. Aguilar‐Salinas(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Lâle Tokgözoğlu(Hacettepe University), Philippe Moulin(Université Claude Bernard Lyon 1), Sander Kersten(Cornell University), Jane K. Stock(European Atherosclerosis Society), Gary F. Lewis(Toronto General Hospital), Robert A. Hegele(Western University), Jan Borén(Göteborgs Stads), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa), M. John Chapman(University of Cambridge), Maurizio Averna(Instituto di Biofisica), Børge G. Nordestgaard(Gentofte Hospital), Erik S.G. Stroes(Amsterdam University Medical Centers), Alice H. Lichtenstein(Tufts University), Daniel Gaudet(Brigham and Women's Hospital), Alan T. Remaley(National Institutes of Health), Brian A. Ference, Bart Staels(Inserm), Anne Tybjærg‐Hansen(University of Copenhagen), Chris J. Packard(University of Glasgow)
Cited by 889
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Atherosclerosis
|Nature Reviews Disease Primers|2019|3k